Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 466

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Simvastatin in the Acute Respiratory Distress Syndrome

Open access
McAuley, Daniel F., Laffey, John G., O'Kane, Cecilia M., Perkins, Gavin D., Mullan, Brian, Trinder, T. John, Johnston, Paul, Hopkins, Philip A., Johnston, Andrew J., McDowell, Cliona, McNally, Christine, the HARP-2 Investigators, for the Irish Critical Care Trials Group·2014·New England Journal of Medicine

Abstract

BACKGROUND: Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients with ARDS. METHODS: In this multicenter, double-blind clinical trial, we randomly assigned (in a 1:1 ratio) patients with an onset of ARDS within the previous 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included the number of days free of nonpulmonary organ failure to day 28, mortality at 28 days, and safety. RESULTS: The study recruited 540 patients, with 259 patients assigned to simvastatin and 281 to placebo. The groups were well matched with respect to demographic and baseline physiological variables. There was no significant difference between the study groups in the mean (±SD) number of ventilator-free days (12.6±9.9 with simvastatin and 11.5±10.4 with placebo, P=0.21) or days free of nonpulmonary organ failure (19.4±11.1 and 17.8±11.7, respectively; P=0.11) or in mortality at 28 days (22.0% and 26.8%, respectively; P=0.23). There was no significant difference between the two groups in the incidence of serious adverse events related to the study drug. CONCLUSIONS: Simvastatin therapy, although safe and associated with minimal adverse effects, did not improve clinical outcomes in patients with ARDS. (Funded by the U.K. National Institute for Health Research Efficacy and Mechanism Evaluation Programme and others; HARP-2 Current Controlled Trials number, ISRCTN88244364.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1403285

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 466

Metadata

Authors
McAuley, D. F., Laffey, J. G., O'Kane, C. M., Perkins, G. D., Mullan, B., Trinder, T. J., Johnston, P., Hopkins, P. A., Johnston, A. J., McDowell, C., McNally, C., & the HARP-2 Investigators, F. T. I. C. C. T. G.
Venue
New England Journal of Medicine
Published
2014-10-30
Volume
371
Issue
18
Pages
1695-1703
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2106410542
Cited by
466
References
19
FWCI
28.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simvastatin in the Acute Respiratory Distress Syndrome. https://app.cochat.ai/papers/10.1056/nejmoa1403285
The paper
McAuley, D. F., Laffey, J. G., O'Kane, C. M., Perkins, G. D., Mullan, B., Trinder, T. J., Johnston, P., Hopkins, P. A., Johnston, A. J., McDowell, C., McNally, C., & the HARP-2 Investigators, F. T. I. C. C. T. G. (2014). Simvastatin in the Acute Respiratory Distress Syndrome. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1403285

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.